BPC-157

BPC-157 is a synthetic 15-residue peptide corresponding to a partial sequence of body protection compound, a protein isolated from human gastric juice. It carries no disulfide bridges, no glycosylation and no terminal modification, which makes it structurally simple relative to most peptides of comparable research interest and contributes to the unusual aqueous stability reported for it.

A recurring observation in the literature is its resistance to degradation in human gastric juice over extended incubation, a property that distinguishes it from most small peptides and that accounts for much of the experimental attention it has received.

The published work originates largely from a single research group and is preclinical throughout, conducted in cell culture and in rat and mouse models. Reported lines of investigation include the vascular endothelial growth factor receptor 2 pathway, downstream Akt and endothelial nitric oxide synthase signalling, and the focal adhesion kinase-paxillin axis associated with cell migration.

In vitro, tendon and ligament fibroblast preparations have been used to examine outgrowth and migration rates, and endothelial tube-formation assays have been used to examine angiogenic signalling. Gastrointestinal lesion models in rodents form a large share of the in vivo literature. The evidence base is entirely preclinical, and the concentration of that literature within one group is a material consideration when weighing replication strength for this compound.

Purity is established by reversed-phase HPLC and identity confirmed by mass spectrometry, reported per lot on the Certificate of Analysis. The sequence contains no cysteine, so the disulfide scrambling and dimerisation that complicate many peptide preparations cannot occur here at all. That structural simplicity is a large part of why consistently high purity is achievable for this compound.

The impurities that do matter are deletion sequences from incomplete coupling and residual trifluoroacetate counter-ion carried through from cleavage and purification. Trifluoroacetate content is worth attention on any peptide destined for cell-based work: it is biologically active in culture at concentrations well below those that would register as a purity problem on the peptide assay itself, and it is a common confounder in experiments that appear to show an effect from the peptide.